PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.67), $1.41 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $164.7 million versus the consensus estimate of $256.93 million.

GUIDANCE:

PTC Therapeutics sees FY2026 revenue of $700-800 million, versus the consensus of $990.3 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.